Profile data is unavailable for this security.
About the company
Neogen Corporation is engaged in developing, manufacturing and marketing a range of products and services dedicated to food and animal safety. The Company operates through two segments: Food Safety and Animal Safety. Its Food Safety segment consists primarily of diagnostic test kits and complementary products sold to food producers and processors to detect dangerous and/or unintended substances in human food and animal feed, such as foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues and general sanitation concerns. Its Animal Safety segment is engaged in the development, manufacture, marketing, and distribution of veterinary instruments, pharmaceuticals, vaccines, topicals, parasiticides, diagnostic products, rodent control products, cleaners, disinfectants, insect control products and genomics testing services for the worldwide animal safety market.
- Revenue in USD (TTM)929.24m
- Net income in USD1.57m
- Incorporated1981
- Employees2.64k
- LocationNeogen Corp620 Lesher PlLANSING 48912-1509United StatesUSA
- Phone+1 (517) 372-9200
- Fax+1 (517) 372-2006
- Websitehttps://www.neogen.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Denali Therapeutics Inc | 295.39m | -137.25m | 2.65bn | 375.00 | -- | 1.82 | -- | 8.96 | -0.9661 | -0.9661 | 2.09 | 10.21 | 0.1976 | -- | -- | 663,797.80 | -9.18 | -14.98 | -10.91 | -17.71 | -- | -- | -46.46 | -104.50 | -- | -- | 0.00 | -- | 204.74 | 20.67 | 55.45 | -- | 30.70 | -- |
| Apogee Therapeutics Inc | 0.00 | -103.55m | 2.67bn | 91.00 | -- | 3.21 | -- | -- | -2.04 | -2.04 | 0.00 | 14.22 | 0.00 | -- | -- | 0.00 | -21.45 | -- | -22.20 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -111.10 | -- | -- | -- |
| 10X Genomics Inc | 625.45m | -264.30m | 2.68bn | 1.26k | -- | 3.73 | -- | 4.29 | -2.24 | -2.24 | 5.30 | 6.01 | 0.6458 | 2.67 | 7.39 | 496,781.60 | -27.29 | -25.52 | -30.80 | -29.05 | 64.62 | 75.88 | -42.26 | -48.53 | 4.45 | -- | 0.00 | -- | 19.81 | 33.43 | -53.67 | -- | 49.15 | -- |
| Azenta Inc | 651.76m | -152.26m | 2.72bn | 3.40k | -- | 1.24 | -- | 4.18 | -2.74 | -2.71 | 11.09 | 40.70 | 0.2242 | 2.86 | 3.44 | 186,216.00 | -5.24 | -0.5934 | -5.64 | -0.6725 | 40.04 | 43.08 | -23.36 | -2.17 | 5.26 | -- | 0.00 | -- | 19.73 | 1.04 | -14.15 | -- | 25.26 | -- |
| Ideaya Biosciences Inc | 15.50m | -128.89m | 2.77bn | 124.00 | -- | 2.92 | -- | 178.43 | -2.00 | -2.00 | 0.2416 | 12.51 | 0.0234 | -- | 64.20 | 125,032.30 | -19.44 | -19.17 | -20.27 | -21.05 | -- | -- | -831.35 | -244.55 | -- | -- | 0.00 | -- | -54.08 | -- | -92.59 | -- | 6.75 | -- |
| Janux Therapeutics Inc | 7.29m | -55.59m | 2.77bn | 64.00 | -- | 4.23 | -- | 380.68 | -1.22 | -1.22 | 0.159 | 12.65 | 0.014 | -- | 11.48 | 113,859.40 | -10.67 | -- | -10.95 | -- | -- | -- | -762.92 | -- | -- | -- | 0.00 | -- | -6.14 | -- | 7.56 | -- | -- | -- |
| Arcellx Inc | 131.66m | -50.54m | 2.78bn | 130.00 | -- | 5.58 | -- | 21.13 | -1.04 | -1.04 | 2.66 | 9.32 | 0.1877 | -- | -- | 1,012,792.00 | -7.21 | -38.82 | -8.96 | -45.41 | -- | -- | -38.39 | -339.38 | -- | -- | 0.0615 | -- | -- | -- | 62.53 | -- | 113.86 | -- |
| PTC Therapeutics, Inc. | 927.56m | -579.22m | 2.79bn | 988.00 | -- | -- | -- | 3.01 | -7.69 | -7.69 | 12.28 | -11.66 | 0.5459 | 2.33 | 4.64 | 938,823.90 | -34.09 | -26.71 | -48.63 | -33.46 | 92.88 | 93.94 | -62.45 | -83.80 | 1.98 | -0.7975 | 1.72 | -- | 34.20 | 28.78 | -12.09 | -- | 32.00 | -- |
| Neogen Corp | 929.24m | 1.57m | 2.85bn | 2.64k | 1,823.86 | 0.9054 | 24.17 | 3.07 | 0.0072 | 0.0072 | 4.29 | 14.52 | 0.2044 | 2.79 | 5.81 | 351,984.10 | 0.0345 | 3.44 | 0.0355 | 3.62 | 50.97 | 47.25 | 0.1685 | 7.77 | 2.66 | 1.31 | 0.2205 | 0.00 | 56.01 | 15.63 | -147.34 | -- | 25.71 | -- |
| Arrowhead Pharmaceuticals Inc | 35.47m | -470.79m | 2.85bn | 525.00 | -- | 5.89 | -- | 80.35 | -4.24 | -4.24 | 0.3189 | 3.90 | 0.0384 | -- | -- | 67,567.62 | -51.72 | -20.02 | -57.39 | -24.65 | -- | -- | -1,346.13 | -61.79 | -- | -80.00 | 0.00 | -- | -1.03 | 71.68 | -16.59 | -- | 162.38 | -- |
| Xenon Pharmaceuticals Inc | 0.00 | -188.60m | 2.87bn | 251.00 | -- | 3.24 | -- | -- | -2.71 | -2.71 | 0.00 | 11.76 | 0.00 | -- | -- | 0.00 | -23.02 | -20.71 | -23.66 | -21.81 | -- | -- | -- | -683.58 | -- | -- | 0.00 | -- | -100.00 | -- | -45.99 | -- | 61.77 | -- |
| Amicus Therapeutics, Inc. | 423.49m | -147.07m | 2.90bn | 517.00 | -- | 22.21 | -- | 6.85 | -0.493 | -0.493 | 1.42 | 0.4413 | 0.5955 | 1.00 | 5.86 | 819,127.70 | -20.68 | -30.65 | -25.76 | -36.55 | 89.62 | 88.94 | -34.73 | -86.10 | 2.61 | -1.36 | 0.7482 | -- | 21.30 | 34.35 | 35.92 | -- | 3.36 | -- |
| SpringWorks Therapeutics Inc | 26.45m | -339.07m | 3.07bn | 305.00 | -- | 5.41 | -- | 116.12 | -5.15 | -5.15 | 0.4007 | 7.66 | 0.0432 | -- | -- | 86,731.15 | -55.31 | -36.97 | -60.58 | -39.49 | 93.86 | -- | -1,281.78 | -2,176.46 | 6.77 | -- | 0.00 | -- | -- | -- | -17.19 | -- | 90.68 | -- |
| Biohaven Ltd | 0.00 | -517.18m | 3.10bn | 239.00 | -- | 9.53 | -- | -- | -6.83 | -6.83 | 0.00 | 3.68 | 0.00 | -- | -- | 0.00 | -99.74 | -- | -123.66 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 28.43 | -- | -- | -- |
Data as of May 31 2024. Currency figures normalised to Neogen Corp's reporting currency: US Dollar USD
56.94%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Mar 2024 | 22.06m | 10.19% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 19.36m | 8.94% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 18.19m | 8.40% |
| Select Equity Group LPas of 31 Mar 2024 | 12.62m | 5.82% |
| Baillie Gifford & Co.as of 31 Mar 2024 | 11.79m | 5.44% |
| William Blair Investment Management LLCas of 31 Mar 2024 | 10.10m | 4.67% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 7.56m | 3.49% |
| Mackenzie Financial Corp.as of 31 Mar 2024 | 7.49m | 3.46% |
| BAMCO, Inc.as of 31 Mar 2024 | 7.30m | 3.37% |
| Conestoga Capital Advisors LLCas of 31 Mar 2024 | 6.87m | 3.17% |
More ▼
Data from 31 Dec 2023 - 31 Mar 2024Source: FactSet Research Systems Inc.
